XML 43 R30.htm IDEA: XBRL DOCUMENT

Research, Consulting and Supply Agreements (Tables)

9 Months Ended

Sep. 30, 2025

The Company’s research and development expenses were comprised of the following (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Clinical studies	$	309	$	582	$	1,636	$	1,880
Manufacturing & Engineering		57		306		381		882
Quality control		221		398		685		1,232
Regulatory		20		151		159		539

Totals	$	607	$	1,437	$	2,861	$	4,533

Costs incurred pursuant to the Amarex agreements were as follows (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Pancreatic Cancer	$	3	$	129	$	199	$	141
Post Covid Conditions		—		28		8		196

Total	$	3	$	157	$	207	$	337

Costs incurred pursuant to the Jubilant agreements were as follows (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Total	$	—	$	—	$	—	$	1

Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Total	$	—	$	133	$	—	$	262

Costs incurred pursuant to the Erasmus agreements were as follows (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Total	$	—	$	—	$	—	$	79

Costs incurred pursuant to the Azenova agreements were as follows (thousands):

	2025		2024		2025		2024
	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024

Total	$	—	$	50	$	—	$	230

Costs incurred pursuant to the Alcami agreements were as follows (thousands):

	2025			2024		2025		2024
	Three months ended September 30,					Nine months ended September 30,
	2025			2024		2025		2024

research and development expenses	$	(5	)	$	—	$	10	$	14